- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
9 Meters Biopharma Inc (NMTRQ)
9 Meters Biopharma Inc stock price live, this page displays OTC NMTRQ stock exchange data. View the NMTRQ premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the 9 Meters Biopharma Inc real time stock price chart below.
What Is the 9 Meters Biopharma Inc Stock Price Today?
The 9 Meters Biopharma Inc stock price today is 0.000100.
What Is the Stock Symbol for 9 Meters Biopharma Inc?
The stock symbol for 9 Meters Biopharma Inc is ""NMTRQ.""
What Stock Exchange Does 9 Meters Biopharma Inc Trade On?
9 Meters Biopharma Inc is listed and trades on the OTC Markets stock exchange.
Is 9 Meters Biopharma Inc a Good Stock to Buy?
Determining whether 9 Meters Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NMTRQ quote. (ISIN: US6544052086)
What Is the 9 Meters Biopharma Inc Stock Price Today?
The 9 Meters Biopharma Inc stock price today is 0.000100.
What Is the Stock Symbol for 9 Meters Biopharma Inc?
The stock symbol for 9 Meters Biopharma Inc is ""NMTRQ.""
What Stock Exchange Does 9 Meters Biopharma Inc Trade On?
9 Meters Biopharma Inc is listed and trades on the OTC Markets stock exchange.
Is 9 Meters Biopharma Inc a Good Stock to Buy?
Determining whether 9 Meters Biopharma Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the NMTRQ quote. (ISIN: US6544052086)
OTC Markets
Currency in USD
0.000100
0.000000(0.00%)
Delayed Data·
Fair Value
An estimate of a Innovate Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.000001
0.000100
52 wk Range
0.000001
0.000300
NMTRQ Scorecard
Full Analysis
Stock has taken a big hit over the last week
Trading near 52-week Low
1/2
Fair Value
An estimate of a Innovate Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.0000010.000100
52 wk Range
0.0000010.000300
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NMTRQ Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Innovate Biopharma's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock generally trades with high price volatility
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Neutral
9 Meters Biopharma Inc Company Profile
9 Meters Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on treatments for people with rare digestive diseases, gastrointestinal conditions with unmet needs, and debilitating disorders in North America. Its lead product candidate is Vurolenatide, a long-acting injectable glucagon-like-peptide-1 that is in Phase 3 clinical trial to treat short bowel syndrome. The company is developing NM-136, a humanized monoclonal antibody for the treatment of obesity and obesity-related disorders; NM-102, a small molecule peptide to prevent antigens from trafficking into systemic circulation; and NM-003, a proprietary long-acting glucagon-like peptide-2 receptor agonist for prevention of acute graft versus host disease. Its partnered product is Larazotide, an 8-amino acid peptide, which is in Phase 2 clinical trial for treatment of multi-system inflammatory syndrome. The company has licensing agreements with Amunix, MHS Care Innovation LLC, Alba Therapeutics Corporation, and EBRIS. 9 Meters Biopharma, Inc. is headquartered in Raleigh, North Carolina. On July 17, 2023, 9 Meters Biopharma, Inc. filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the Eastern District of North Carolina.
Compare NMTRQ to Peers and Sector
Metrics to compare | NMTRQ | Sector Sector - Average of metrics from a broad group of related Financial sector companies | Relationship RelationshipNMTRQPeersSector | |
|---|---|---|---|---|
P/E Ratio | 0.0x | −0.5x | −0.5x | |
PEG Ratio | 0.00 | 0.00 | 0.00 | |
Price/Book | 0.0x | 0.9x | 2.6x | |
Price / LTM Sales | 0.0x | 1.3x | 3.3x | |
Upside (Analyst Target) | 0.0% | 206.1% | 42.9% | |
Fair Value Upside | Unlock | 12.4% | 6.2% | Unlock |
Earnings
Latest Release
May 15, 2023
EPS / Forecast
-1.02 / -0.78
Revenue / Forecast
-- / --
FAQ
What Stock Exchange Does Innovate Biopharma Trade On?
Innovate Biopharma is listed and trades on the OTC Markets stock exchange.
What Is the Stock Symbol for Innovate Biopharma?
The stock symbol for Innovate Biopharma is "NMTRQ."
What Is the Innovate Biopharma Market Cap?
As of today, Innovate Biopharma market cap is 1.45K.
What Is Innovate Biopharma's Earnings Per Share (TTM)?
The Innovate Biopharma EPS (TTM) is -3.53.
From a Technical Analysis Perspective, Is NMTRQ a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Innovate Biopharma Stock Split?
Innovate Biopharma has split 2 times.
How Many Employees Does Innovate Biopharma Have?
Innovate Biopharma has 10 employees.
What is the current trading status of Innovate Biopharma (NMTRQ)?
As of 12 Aug 2025, Innovate Biopharma (NMTRQ) is trading at a price of 0.00, with a previous close of 0.00. The stock has fluctuated within a day range of 0.00 to 0.00, while its 52-week range spans from 0.00 to 0.00.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.